RHYTHM PHARMACEUTICALS INC. - COMMON STOCK

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

10 янв 2025 06:15:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

20 дек 2024 13:15:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

03 дек 2024 05:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

18 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

13 ноя 2024 17:30:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

06 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

05 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

04 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

24 окт 2024 05:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024

23 окт 2024 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

08 окт 2024 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

16 сен 2024 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

26 авг 2024 07:02:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September

26 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

13 авг 2024 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

06 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

31 июл 2024 08:10:21 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

23 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire